South Korea has passed two million foreign patients in a single year for the first time since it began compiling the figures in 2009. The Ministry of Health and Welfare reported that 2,011,822 foreign patients travelled to Korea for treatment last year, a total that set records for three years running. Chinese patients drove much of that growth, and for the first time they were the largest single group of arrivals. The headline is medical tourism. Underneath, the detail is mostly aesthetic dermatology and reconstructive surgery.
Ministry of Health and Welfare confirms record foreign patient numbers
Each year the Ministry of Health and Welfare compiles the figures under the Medical Overseas Expansion Act, breaking them down by nationality and by the specialities patients seek. Its report put last year’s total at 2,011,822 foreign patients, up from roughly 1.17 million in 2024 and just over 610,000 in 2023. That is a run of record years at a pace few destinations sustain. Korea now sits in a small group of countries that treat foreign patients at this scale, and the government is reading the two-million mark as a threshold rather than a ceiling.
Chinese patients overtake Japan for the first time
Foreign patients arrived from 201 countries last year, with China, Japan, Taiwan, the United States and Thailand the five largest sources. China accounted for 30.8 per cent of the total, or 618,973 patients, while Japan followed with 29.8 per cent and 600,009 patients. Taiwan contributed 9.2 per cent, or 185,715 patients. Until 2024 Japanese patients were the largest group, and last year’s switch to China at the top marks a real shift in where Korea’s medical tourism demand comes from. Arrivals from China and Taiwan both more than doubled their rate of increase on the previous year, the Ministry of Health and Welfare reported. Much of that jump tracks visa-free entry for Chinese group tourists, alongside the wider recovery in travel and steady demand for cosmetic and dermatological treatment.
Western markets grow alongside Asia
Growth was not confined to East Asia. United States patients rose 70.4 per cent year on year to 173,363, the Ministry of Health and Welfare reported, while Canadian patients rose 59.1 per cent to 23,624. Both were the highest totals recorded since the count began in 2009. A broader spread of source markets gives Korea some cushion against a downturn in any one country, and that spread is healthier than the headline concentration suggests. The top two nationalities together still account for well over half of all foreign patients. That is a concentration worth watching.
Dermatology and plastic surgery dominate the numbers
Specialities tell the clearest story. Dermatology alone accounted for 62.9 per cent of foreign patients, or 1,312,700 people, and reconstructive plastic surgery added another 11.2 per cent, or 233,100 people. Between them, dermatology and reconstructive plastic surgery made up close to three-quarters of Korea’s foreign patient volume last year. These are largely elective, self-funded procedures, and Korea has built accredited clinics, aesthetic dermatology and cosmetology brands around them. On the health tourism spectrum this sits at the cosmetic end, medically performed but aesthetically motivated, closer to the wellness line than to the clinical core of medical tourism. Korea’s two-million story is, in plain terms, a skin and cosmetic surgery story. Calling it medical tourism is accurate but incomplete.
The economic case and the concentration risk
The Korea Institute for Industrial Economics and Trade estimated that the 2.01 million foreign patients and their companions spent 12.5 trillion won last year. Medical treatment made up 3.3 trillion won of that, and the wider spending generated added value of more than 10 trillion won for the economy. Those figures explain why the government treats medical tourism as a strategic export industry rather than a peripheral niche. The risk sits on the demand side. Korea’s growth now leans heavily on Chinese arrivals and on a visa-free policy that a single administration can reverse, which is the classic exposure of a destination economy built on one dominant source market. If Beijing tightened group-tourist entry, Korea’s dermatology clinics would feel it first and fastest. This is the facilitator’s market as much as the clinic’s, and the middlemen who sell visibility rather than trust cluster on the busiest inbound corridor, which for Korea now runs from mainland China.
From volume to value in Korean medical tourism
Having crossed two million foreign patients, the Ministry of Health and Welfare has signalled a shift from chasing headline numbers to managing quality and accreditation. That is the right instinct for a destination this concentrated. The durable version of Korean medical tourism widens beyond aesthetics into accredited specialities such as oncology, orthopaedics and reproductive medicine, where the country competes on clinical outcomes and aftercare rather than price, and it spreads demand across more than two source markets. That means investment in accreditation, in clinician referral pathways, and in oncology and cardiology capacity that a dermatology-led boom does not build on its own. The two-million figure is a real achievement, and it is also a prompt to fix the underlying machinery before leaning harder on the brand. Korea has the scale. The open question is whether it can broaden the base that produced it.
